UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of March 2022.
Commission File Number: 001-40530
GH Research PLC
(Exact name of registrant as specified in its charter)
28 Baggot Street Lower
Dublin 2
D02 NX43
Ireland
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
|
Form 20-F
|
☒
|
Form 40-F
|
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
On March 28, 2022, GH Research PLC (the “Company”) issued a press release announcing its full year 2021 financial results and providing certain business updates. A copy the press release is attached hereto as Exhibit 99.1.
In connection with the release of these updates, on March 28, 2022, the Company made available on its website an updated corporate presentation. A copy of the corporate presentation is attached hereto as Exhibit 99.2. The fact that this
presentation is being made available and furnished herewith should not be deemed an admission as to the materiality of any information contained in the materials. The information contained in the presentation is being provided as of March 28, 2022
and the Company does not undertake any obligation to update the presentation in the future nor to update forward-looking statements to reflect subsequent actual results.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
GH Research PLC
|
||
|
Date: March 28, 2022
|
||
|
By:
|
/s/ Julie Ryan
|
|
|
Name:
|
Julie Ryan
|
|
|
Title:
|
Vice President, Finance
|
|
EXHIBIT INDEX
|
Exhibit No.
|
Description
|
|
Press release dated March 28, 2022
|
|
|
Corporate Presentation dated March 28, 2022
|
Exhibit 99.1
GH Research Reports Full Year 2021 Financial Results and Provides Business Updates
Dublin, Ireland, March 28, 2022 – GH Research PLC (Nasdaq: GHRS), a
clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the full year ended December 31, 2021 and gave updates on its business.
Fourth Quarter 2021 Business Highlights
In December 2021, we reported the successful outcome of the Phase 2 part of our Phase 1/2 clinical trial of GH001, our proprietary inhalable 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) product candidate, in patients with treatment-resistant
depression (TRD) (GH001-TRD-102). The primary endpoint of the Phase 2 part of the trial was met with 7 of 8 patients (87.5%) in remission (Montgomery–Åsberg Depression Rating Scale (MADRS) ≤10) at day 7 after dosing (p<0.0001). Patients followed a
proprietary individualized dosing regimen (IDR) with up to three increasing GH001 doses (6 mg, 12 mg and 18 mg) on a single day. No serious and no severe adverse events, no clinically significant changes in any of the safety laboratory analyses,
vital signs, psychiatric safety assessments or measures of cognitive function and no signal for suicidal ideation or behavior were observed.
Furthermore, we reported positive preliminary safety results from a Phase 1 clinical pharmacology trial in healthy volunteers (GH001-HV-103), which supported the safety profile of GH001 single doses (6 mg, 12 mg and 18 mg) and the proprietary
GH001 IDR with up to three increasing GH001 doses (6 mg, 12 mg and 18 mg) on a single day, given in two dose intervals (1 hour, 2 hours).
Full Year 2021 Financial Highlights
Cash position
Cash was $276.8 million as of December 31, 2021, compared to $5.9 million as of December 31, 2020.
Research and development expenses
R&D expenses were $8.6 million for the year ended December 31, 2021, compared to $338 thousand for the full year 2020. The increase was primarily due to increased activities relating to our technical developments and clinical trials and
increases in employee expenses to support these activities.
General and administrative expenses
G&A expenses were $6.5 million for the year ended December 31, 2021, compared to $108 thousand for the full year 2020. The increase was primarily due to higher professional and compliance fees associated with being a public company, as well as
increased employee expenses.
Net loss
Net loss was $9.2 million, or $0.211 loss per share, for the year ended December 31, 2021, compared to $446 thousand, or $0.016 loss per share, for the full year 2020.
|
|
Business Updates
GH001 for the treatment of TRD
We plan to submit clinical trial applications in several European countries for a multi-center, randomized, controlled Phase 2b trial of GH001 in TRD (GH001-TRD-201) in the third quarter of 2022.
GH001 for the treatment of additional disorders
We have recently submitted clinical trial applications in a European country for a Phase 2a proof-of-concept clinical trial of GH001 for the treatment of patients with bipolar II disorder and a current depressive
episode (GH001-BD-202) and for a Phase 2a proof-of-concept clinical trial of GH001 for the treatment of patients with postpartum depression (GH001-PPD-203). We expect to submit further clinical trial applications for these trials in additional
European countries. Pending regulatory clearance, we expect to initiate these trials in the third quarter of 2022.
GH001 in healthy volunteers
We now have the final safety results of our Phase 1 clinical pharmacology trial in healthy volunteers (GH001-HV-103) and the data continue to support the safety profile of GH001 single doses and the proprietary GH001 IDR. Results from
pharmacokinetic analyses were aligned with the ultra-rapid onset and short duration of observed psychoactive effects. Results of cognitive function tests as well as psychoactive effect assessments were aligned with results of previous trials. The
full results of the trial support that an interval down to 1 hour between individual doses of the IDR is feasible for use in future clinical trials.
Other GH001 regulatory interactions
We have recently submitted a request for a pre-IND meeting with the FDA to discuss our planned filing of a U.S. IND for GH001
in TRD. The meeting has been granted by the FDA for the second quarter of 2022. The proposed IND-opening study is a Phase 1 imaging study in patients with TRD designed to further elucidate the
mechanism of action of GH001 (GH001-TRD-104). There are no current plans for additional regulatory meetings with other agencies.
Intellectual property
We have recently filed a number of new patent applications, which have not yet been published, that relate to further aspects of 5-MeO-DMT use in a therapeutic context, including novel manufacturing methods of 5-MeO-DMT, novel salt forms of
5-MeO-DMT and novel uses of 5-MeO-DMT.
Financial
Cash was approximately $273.8 million as of February 28, 2022, and we believe that our existing cash will be sufficient for us to fund our operating expenses and capital expenditure requirements into 2025.
|
|
Filing of Annual Report on Form 20-F
In connection with the announcement of our full year 2021 financial highlights, we have filed our annual report on Form 20-F with the U.S. Securities and Exchange Commission. The annual report is available on our website at www.ghres.com and
shareholders may receive a hard copy free of charge upon request.
About GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the
treatment of patients with treatment-resistant depression (TRD).
About GH001
Our lead product candidate, GH001, is formulated for 5-MeO-DMT administration via a proprietary inhalation approach. With GH001, we have completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with
treatment-resistant depression (TRD). Based on the observed clinical activity, where 87.5% of patients with TRD were brought into an ultra-rapid remission with our GH001 individualized single-day dosing regimen in the Phase 2 part of the trial, we
believe that GH001 has potential to change the way TRD is treated today. Across the GH001 program, no serious adverse events have been reported and GH001 was well tolerated at the investigated single dose levels and in the individualized dosing
regimen.
About GH002 and GH003
GH002 is our 5-MeO-DMT product candidate formulated for administration via a proprietary injectable approach. GH003 is our 5-MeO-DMT product candidate formulated for administration via a proprietary intranasal
administration approach. GH002 and GH003 are currently in preclinical development, and we anticipate developing them in subpopulations and confined use scenarios within our focus area of psychiatric and neurological disorders.
Forward-Looking Statements
This press release contains statements that are, or may deemed to be, forward-looking statements. All statements other than statements of historical fact included in this press release, including statements regarding our future results of
operations and financial position, our cash runway, business strategy, product candidates, research pipeline, ongoing and currently planned preclinical studies and clinical trials, regulatory submissions and approvals, research and development costs,
timing and likelihood of success, as well as plans and objectives of management for future operations are forward-looking statements. Forward-looking statements appear in a number of places in this press release and include, but are not limited to,
statements regarding our intent, belief or current expectations. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and
uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including, but not limited to, those described in our filings with the U.S. Securities and Exchange
Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this document speak only as of the date of this press release. We expressly disclaim any obligation or undertaking to update
these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based unless required to do so by applicable law. No
representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
|
|
Investor Relations:
Julie Ryan
GH Research PLC
investors@ghres.com
|
|
GH RESEARCH PLC
Consolidated Statement of Comprehensive Income
(in thousands, except share and per share amounts)
|
Year ended
December 31,
|
||||||||||||
|
2021
|
2020
|
2019
|
||||||||||
|
$
|
’000
|
$
|
’000
|
$
|
’000
|
|||||||
|
Operating expenses
|
||||||||||||
|
Research and development
|
(8,553
|
)
|
(338
|
)
|
(296
|
)
|
||||||
|
General and administration
|
(6,547
|
)
|
(108
|
)
|
(14
|
)
|
||||||
|
Loss from operations
|
(15,100
|
)
|
(446
|
)
|
(310
|
)
|
||||||
|
Finance expense
|
(9
|
)
|
—
|
—
|
||||||||
|
Foreign currency translation differences
|
5,907
|
—
|
—
|
|||||||||
|
Loss before tax
|
(9,202
|
)
|
(446
|
)
|
(310
|
)
|
||||||
|
Tax charge/(credit)
|
—
|
—
|
—
|
|||||||||
|
Loss for the year
|
(9,202
|
)
|
(446
|
)
|
(310
|
)
|
||||||
|
Other comprehensive income/(expense)
|
||||||||||||
|
Items that may be reclassified to profit or loss Currency translation adjustment
|
(6,103
|
)
|
212
|
(12
|
)
|
|||||||
|
Total comprehensive loss for the year
|
(15,305
|
)
|
(234
|
)
|
(322
|
)
|
||||||
|
Attributable to owners:
|
||||||||||||
|
Loss for the year
|
(9,202
|
)
|
(446
|
)
|
(310
|
)
|
||||||
|
Comprehensive loss for the year
|
(15,305
|
)
|
(234
|
)
|
(322
|
)
|
||||||
|
Loss per share
|
||||||||||||
|
Basic and diluted loss per share (in USD)
|
(0.211
|
)
|
(0.016
|
)
|
(0.011
|
)
|
||||||
|
|
GH RESEARCH PLC
Consolidated Balance Sheet
(in thousands)
|
At December 31,
|
||||||||
|
2021
|
2020
|
|||||||
|
$
|
’000
|
$
|
’000
|
|||||
|
ASSETS
|
||||||||
|
Current assets
|
||||||||
|
Cash and cash equivalents
|
276,776
|
5,895
|
||||||
|
Other current assets
|
3,066
|
17
|
||||||
|
Total current assets
|
279,842
|
5,912
|
||||||
|
Non-current assets
|
||||||||
|
Property, plant and equipment
|
82
|
—
|
||||||
|
Total non-current assets
|
82
|
—
|
||||||
|
Total assets
|
279,924
|
5,912
|
||||||
|
LIABILITIES AND EQUITY
|
||||||||
|
Current liabilities
|
||||||||
|
Trade payables
|
883
|
1
|
||||||
|
Other current liabilities
|
1,866
|
245
|
||||||
|
Total current liabilities
|
2,749
|
246
|
||||||
|
Total liabilities
|
2,749
|
246
|
||||||
|
Equity attributable to owners
|
||||||||
|
Share capital
|
1,301
|
871
|
||||||
|
Additional paid-in capital
|
291,448
|
5,430
|
||||||
|
Other reserves
|
366
|
—
|
||||||
|
Foreign currency translation reserve
|
(5,903
|
)
|
200
|
|||||
|
Accumulated deficit
|
(10,037
|
)
|
(835
|
)
|
||||
|
Total equity
|
277,175
|
5,666
|
||||||
|
Total liabilities and equity
|
279,924
|
5,912
|
||||||
Exhibit 99.2
1 Corporate PresentationGH Research PLC (NASDAQ: GHRS) GH Research March 2022 2022© GH Research
PLC
Disclaimer Regarding Forward-Looking Statements This presentation has been prepared by GH Research PLC
(“GH Research”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or GH Research or any director,
employee, agent, or adviser of GH Research. This presentation does not purport to be all-inclusive or to contain all of the information you may desire.This presentation does not constitute an offer to sell or the solicitation of an offer to buy
securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or
jurisdiction. 2 This presentation contains forward-looking statements, all of which are qualified in their entirety by this cautionary statement. Many of the forward-looking statements contained herein can be identified by the use of
forward-looking words such as “may”, “anticipate”, “believe”, “could’, “expect”, “should”, “plan”, “intend”, “estimate”, “will”, “potential” and “ongoing”, among others, although not all forward-looking statements contain these identifying
words.Any statements contained herein that do not describe historical facts are forward-looking statements that are based on management’s expectations and are subject to certain factors, risks and uncertainties that may cause actual results,
outcomes, timing and performance to differ materially from those expressed or implied by such statements. These factors, risks and uncertainties include, but are not limited to: the costs and uncertainties associated with GH Research’s research
and development efforts; the inherent uncertainties associated with the conduct, timing and results of nonclinical and clinical studies of GH Research’s product candidates; GH Research’s ability to obtain, maintain, enforce and defend issued
patents; the adequacy of GH Research’s capital resources, the availability of additional funding and GH Research’s cash runway; and other factors, risks and uncertainties described in GH Research’s filings with the U.S. Securities and Exchange
Commission. Except as otherwise noted, these forward-looking statements speak only as of the date of this presentation, and GH Research undertakes no obligation to update or revise any of such statements to reflect events or circumstances
occurring after this presentation. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond GH Research’s control, you should not rely on
these forward-looking statements as predictions of future events. The events and circumstances reflected in any such forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the
forward-looking statements. GH Research cautions you not to place undue reliance on the forward-looking statements contained in this presentation. 2022© GH Research PLC
SeekingUltra-Rapid, Durable Remissionsin Depression 3 2022© GH Research PLC
Pipeline 4 2022© GH Research PLC Stage of
Development PROGRAMS INDICATION PRECLINICAL PHASE 1 PHASE 2a PHASE 2b PHASE 3 Next Stage GH0015-MeO-DMT for inhalation administration Treatment-Resistant Depression (TRD) Initiate Phase 2b trial in TRD
(GH001-TRD-201) Bipolar II Disorder (BDII)* Initiate Phase 2a trial in BDII(GH001-BD-202) Postpartum Depression (PPD)* Initiate Phase 2a trial in PPD(GH001-PPD-203) GH002 / GH0035-MeO-DMT for injection / intranasal
administration Psychiatric or Neurological Disorder Complete preclinical development Complete *In light of our completed Phase 1 clinical trials of GH001 in healthy volunteers and our completed Phase 1/2 trial in TRD, we
recently submitted clinical trial applications to begin two Phase 2a trials in patients with BDII and a current major depressive episode and in patients with PPD, respectively. We believe that we can proceed to Phase 2a trials for these two
indications based on existing preclinical and clinical data for GH001.
... Remission Rates in TRD < 15% Established Therapies are Slow-Acting ~33% no remission despite 4
treatment steps Adapted from Trivedi et al., Am J Psychiatry 2006 and Rush et al., Am J Psychiatry 2006 Average time to remission is ~6 weeks (STAR*D study, Remission Rate Over Time, Treatment Step 1 = Citalopram) The Problem for Patients
with Depression (STAR*D study, Remission Rates Treatment Steps 1 to 4) 5 2 or more prior therapies = TRD 2022© GH Research PLC
Large and Open Depression Market in the EU and US 6 First Line MDD Second Line
MDD Treatment-Resistant Depression (TRD) Patients cycle through ineffective therapies for TRD Diagnosed: ~48MTreated (pharmacotherapy ± psychotherapy): ~24M Non-response to first line: ~13M Non-response to two prior lines:
~9M Company estimates based on: https://www.nimh.nih.gov/health/statistics/major-depression.shtml; Wittchen et al., The size and burden of mental disorders and other disorders of the brain in Europe 2010, European Neuropsychopharmacology
(2011); Rush et al., Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report, Am J Psychiatry 2006MDD, Major Depressive Disorder 2022© GH Research PLC
5-MeO-DMT (5-Methoxy-N,N-Dimethyltryptamine)Naturally-occurring psychoactive substance from tryptamine
classHighly potent agonist on 5-HT1A and 5-HT2A receptorsPsychoactive effects with ultra-rapid onset (within seconds) and short duration (5 to 30 min)High propensity to induce peak experiences (PE), which may be a surrogate marker for
therapeutic effectsGH001 (5-MeO-DMT administration via a proprietary inhalation approach)Intraday individualized dosing regimen for maximization of ultra-rapid remissions Single visit initial treatment, with no structured psychotherapy
Potential for convenient and infrequent retreatment 5-MeO-DMT and GH001 7 2022© GH Research PLC 5-MeO-DMT Foundational IP
GH001 Single Dose: GH001 Individualized Dosing Regimen (IDR): More Chances for Remission MADRS
score MADRS score MADRS score MADRS score Dose 1 Dose 1 Dose 2 Dose 3 Dose 2 Dose 1 No remission Remission Remission Remission Remission Hypothetical Patient 1 Hypothetical Patient 2 Hypothetical Patient
3 Hypothetical Patient 1 Hypothetical Patient 2 No remission No remission No remission Dose 1 GH001 – Individualized Dosing Regimen (IDR) Designed to Achieve Ultra-Rapid and Durable Remissions 8 2022© GH Research PLC MADRS
score Dose 1
Phase 1 Trial in Healthy Volunteers GH001-HV-101(Completed) 9 Clinicaltrials.gov ID NCT04640831 2022©
GH Research PLC
GH001Administration Day 1 Day 7 GH001 2 mg (n=4) GH001 6 mg (n=6) GH001 12 mg (n=4) GH001 18
mg (n=4) HV(n=18) Part A (Single Dose) Part B (IDR) Primary Endpoint:Safety until day 7Peak Experience Scale (PE Scale)1 HV(n=4) Primary Endpoint:Safety until day 7Peak Experience Scale (PE Scale)1 GH001 IDR6, 12, 18 mg to achieve PE(up
to 3 doses, 3h interval) Key Assessments SafetyPE ScaleCognitive function Safety SafetyCognitive function 1The PE Scale averages answers scored by the subject by marking a visual analogue scale between 0 and 100 for the following three
questions: 1. How intense was the experience; 2. To what extent did you lose control; 3. How profound (i.e., deep and significant) was the experience? Design of Phase 1 Trial in Healthy Volunteers (GH001-HV-101) 10 2022© GH Research PLC PE,
Peak ExperienceIDR, Individualized Dosing Regimen
Study Safety Group reviewNo SAEsAll ADRs mild, except two moderate (*)All ADRs resolved
spontaneouslyInhalation well-toleratedNo noteworthy changes in vital parameters, except for temporary, non-clinically relevant increase in heart rate and blood pressure shortly after administration of GH001No clinically significant changes in
safety laboratory analyses, psychiatric safety assessments or measures of cognitive function ADRs Part A (Single Dose) Part B (IDR) ADRs 2 mg (N=4) 6 mg (N=6) 12 mg (N=4) 18 mg (N=4) IDR1 (N=4) MedDRA Preferred
Term n n n n n Abnormal dreams 1 Anxiety 1 1 Clumsiness 1 Confusional state 1 Euphoric mood 1 Fatigue 1 1* Feeling
hot 1 Flashback 1 Hallucination 1 Head discomfort 1 Headache 2 1 1 Heart rate increased 1* Hyperacusis 1 Insomnia 1 Mental
fatigue 1 Nausea 2 1 1 2 Vision blurred 1 Part A (Single Dose) and Part B (IDR) – Safety 11 Adverse Drug Reaction, or ADR, an adverse event with a relationship code to the investigational product of
definite, probable, or possible, or where code is missingIDR, Individualized Dosing Regimen 2022© GH Research PLC 16 mg (N=1); 6-12 mg (N=2); 6-12-18 mg (N=1)
Average fordose group PE Scale PEThreshold Part A – Peak Experience (PE) Dose-Effectsand
Inter-Person Variability 12 PE, Peak Experience 2022© GH Research PLC
PEThreshold Part B – Peak Experience (PE)Effect of Intraday Individualized Dosing
Regimen 13 PE, Peak Experience 2022© GH Research PLC
Phase 1/2 Trial inTreatment-Resistant DepressionGH001-TRD-102(Completed) 14 Clinicaltrials.gov ID
NCT04698603 2022© GH Research PLC
Key Assessments MADRS 2-hrsPE ScaleSafety MADRS 1-dayCognitive functionSafety MADRS 7-dayCognitive
functionSafety GH001Administration Day 1 Day 7 Design of Phase 1/2 Trial in TRD (GH001-TRD-102) 15 PE, Peak Experience; MADRS, Montgomery-Åsberg Depression Rating ScaleIDR, Individualized Dosing Regimen 1Defined as inadequate
response to at least two adequate courses of pharmacological therapy or one adequate course of pharmacological therapy and at least one adequate course of evidence-based psychotherapy 2022© GH Research PLC Phase 1 (Single Dose) Phase 2
(IDR) GH001 12 mg (n=4) GH001 18 mg (n=4) TRD1(n=8) Primary Endpoint:Safety until day 7 TRD1(n=8) Primary Endpoint:MADRS remission day 7 (MADRS≤10) GH001 IDR6, 12, 18 mg to achieve PE(up to 3 doses, 3h interval)
Phase 1 (Single Dose) and Phase 2 (IDR) – Safety 16 Adverse Drug Reaction, or ADR, an adverse event
with a relationship code to the investigational product of definite, probable, or possible, or where code is missingIDR, Individualized Dosing Regimen; C-SSRS, Columbia-Suicide Severity Rating Scale 2022© GH Research PLC Study Safety Group
reviewNo SAEsAll ADRs mild, except three moderate*All ADRs resolved spontaneouslyInhalation well-toleratedNo noteworthy changes in vital parameters, except for temporary, non-clinically relevant increase in heart rate and blood pressure shortly
after administration of GH001No clinically significant changes in safety laboratory analyses, psychiatric safety assessments or measures of cognitive functionNo safety signal relating to suicidal ideation or suicidal behavior, based on C-SSRS
and MADRS subscore item “suicidal thoughts” ADRs Phase 1 (Single Dose) Phase 2 (IDR) ADRs 12 mg (N=4) 18 mg (N=4) IDR1 (N=8) MedDRA Preferred Term n n n Abdominal discomfort 1 Anxiety 2 Depressive
symptom 1* Dizziness 1 Feeling abnormal 1 1 Flashback 1 1 2 Headache 2 1 3 Muscle discomfort 1 Muscle spasms 1 Nausea 2* Paresthesia 1 Sensory disturbance 3 16-12 mg (N=6);
6-12-18 mg (N=2)
MADRS Remission / Response / Improvement Rate Day 7 Phase 1 (Single Dose) – Efficacy (MADRS) 17 PE,
Peak Experience; MADRS, Montgomery–Åsberg Depression Rating ScaleMADRS remission = MADRS of ≤10; MADRS response = Reduction of ≥50% from baseline in MADRS. 2022© GH Research PLC 2 of 4 (50%) in the 12 mg group and1 of 4 (25%) in the 18 mg
group had a MADRS remission at day 72 of 8 patients had a PE and both had a MADRS remission at day 7
Phase 2 (IDR) – Efficacy (MADRS) 18 2022© GH Research PLC MADRS Remission / Response / Improvement
Rate Day 7 Primary endpoint met: 7 of 8 patients (87.5%) had a MADRS remission at day 7, p<0.00017 of 8 patients had a PE and 6 of those had a MADRS remission at day 7 PE, Peak Experience; MADRS, Montgomery–Åsberg Depression Rating
ScaleMADRS remission = MADRS of ≤10; MADRS response = Reduction of ≥50% from baseline in MADRS.
Phase 2 (IDR) – Efficacy (MADRS Change from Baseline) 2022© GH Research PLC Baseline1 2 hours Day
1 Day 7 GH001 19 p=0.0018 p<0.0001 p<0.0001 Primary endpoint met: 7 of 8 patients (87.5%) had a MADRS remission at day 7, p<0.00017 of 7 remissions from day 1 and5 of 7 remissions from 2 hours 1Baseline mean MADRS=32
MADRS and PE – Observed Improved Outcome in Phase 2 (IDR) vs Phase 1 (Single Dose) Phase 2
(IDR) Phase 1 (Single Dose) 12 mg Phase 1 (Single Dose) 18 mg MADRS Remission Rate Day 7 87.5% (7 of 8) 50% (2 of 4) 25% (1 of 4) Mean MADRS Change Day 7 -24.4 (-76%) -21.0 (-65%) -12.8 (-41%) Rate of PE 87.5% (7 of 8) 50% (2 of
4) 0% (0 of 4) Mean PE Score 90.4 (at final dose) 58.2 59.1 2022© GH Research PLC 20 PE, Peak Experience; MADRS, Montgomery-Åsberg Depression Rating ScaleIDR, Individualized Dosing Regimen
Phase 1 Clinical Pharmacology Trial in Healthy Volunteers GH001-HV-103(Completed) 21 2022© GH Research
PLC
GH001Administration Day 7 GH001 6 mg (n=8+2 placebo) GH001 12 mg (n=8+2 placebo) GH001 18 mg
(n=8+2 placebo) HV(n=30) Single-Dose Part IDR Part HV(n=16) GH001 IDR6, 12, 18 mg to achieve PE(up to 3 doses, 1h interval, n=8) Key Assessments SafetyPharmacokineticsPE ScaleCognitive function SafetyCognitive
function Safety 22 Day 30 GH001 IDR6, 12, 18 mg to achieve PE(up to 3 doses, 2h interval, n=8) Primary Endpoint:Pharmacokinetic profile of 5-MeO-DMT and bufotenine 2022© GH Research PLC Design of Phase 1 Clinical Pharmacology Trial
in Healthy Volunteers (GH001-HV-103) PE, Peak ExperienceIDR, Individualized Dosing Regimen
Safety ReviewNo SAEs All ADRs mildAll ADRs resolved spontaneouslyInhalation well-toleratedNo noteworthy
changes in vital parameters, except for temporary, non-clinically relevant increase in heart rate and blood pressure shortly after administration of GH001No clinically relevant changes in ECG, safety laboratory analyses, peak flow, cognitive
function, psychiatric safety assessments, including the C-SSRSFurther ResultsPharmacokinetic analyses and psychoactive effect assessments (PE Scale) support that an interval down to 1 hour between individual doses of the IDR is feasible for
future clinical trials Single Dose and IDR – Safety and Further Results 23 Adverse Drug Reaction, or ADR, an adverse event with a relationship code to the investigational product of definite, probable, or possible, or where code is
missingIDR, Individualized Dosing Regimen; C-SSRS, Columbia-Suicide Severity Rating Scale; PE, Peak Experience 2022© GH Research PLC ADRs Single-dose IDR 6 mg (N=8) 12 mg (N=8) 18 mg (N=8) Placebo (N=6) 1h interval
(N=8)2 2h interval (N=8)3 MedDRA Preferred Term n n n n n n Abnormal dreams 1 Chest discomfort 1 Crying 2 2 Dizziness 1 Dry
mouth 1 Dyskinesia 1 Fatigue 1 2 1 Headache 3 1 1 1 Hypoesthesia oral 1 Paresthesia
oral 1 Retching 1 Somnolence 1 Tachycardia 2 Tension 1 Tremor 1 26 mg (N=1), 6-12 mg (N=3); 6-12-18 mg (N=4)36-12 mg (N=3); 6-12-18 mg (N=5)
LAYER 1: REGULATORY EXCLUSIVITYFDA: 5 years (+2.5 years paragraph IV stay)EMA: 10 years (+1 year
for new indication) LAYER 3: TECHNICALComplex bioequivalence for systemically-acting inhalation/intranasal products with high intra- and inter-subject variability LAYER 2: PATENTSSeveral patent applications filed: Novel aerosol compositions
of matter of 5-MeO-DMTNovel manufacturing methods and novel salt forms of 5-MeO-DMTNovel uses of 5-MeO-DMT in various disorders (including inhaled, intranasal, i.v., i.m., s.c., and other routes) Three-Layer Protection Strategy 24 2022© GH
Research PLC
Board of Directors & Management 25 Florian Schönharting Michael Forer MScChairman of the Board,
Co-founder BA, LLBBoard Member 2022© GH Research PLC Dermot Hanley Duncan Moore BSC, MBABoard Member MPhil, PhDBoard Member Theis Terwey PD Dr. med. CEO, Co-founder Julie Ryan ACA, MAcc, BCommVP, Finance Magnus Halle BScManaging
Director, Ireland, Co-founder
Scientific Advisors 26 Michael Thase M.D.Professor of Psychiatry, Perelman School of
MedicineUniversity of Pennsylvania Madhukar Trivedi M.D.Professor of Psychiatry,UT Southwestern Medical Center Mark Zimmerman M.D.Professor of Psychiatry and Human Behavior,Brown University Eduard Vieta Prof. Dr. Head, Psychiatry
Unit,Hospital Clínic de Barcelona Michael Bauer Prof. Dr. rer. nat. Dr. med.Chair, Department of Psychiatry and Psychotherapy,Technische Universität Dresden Malek Bajbouj Prof. Dr. med.Head, Center for Affective Neuroscience,Charité,
Berlin Johannes Ramaekers Prof. Dr.Professor, Faculty of Psychologyand Neuroscience of Maastricht University 2022© GH Research PLC
Anticipated Milestones and Financial Overview GH001Submit clinical trial applications for multi-center,
randomized, controlled Phase 2b trial in TRD in 3Q 2022Initiate Phase 2a trials in BDII and in PPD in 3Q 2022Hold pre-IND meeting with the FDA for GH001 in TRD in 2Q 2022GH002 and GH003Complete preclinical development and initiate Phase 1 trial
in healthy volunteersFinancial Overview Cash was $276.8 million as of December 31, 2021We believe existing cash will be sufficient to fund operating expenses and capital expenditure requirements into 2025 27 2022© GH Research PLC
SeekingUltra-Rapid, Durable Remissionsin Depression 28 2022© GH Research PLC